1
|
Liang Z, Liu L, Zhou Y, Liu W, Lu Y. Research Progress on Bioactive Metal Complexes against ER-Positive Advanced Breast Cancer. J Med Chem 2023; 66:2235-2256. [PMID: 36780448 DOI: 10.1021/acs.jmedchem.2c01458] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
Breast cancer is the most prevalent cancer in women and represents a serious disease that is harmful to life and health. In 1977, with the approval of tamoxifen, endocrine therapy has become the main clinical treatment for ER-positive (ER+) breast cancer. Although patients initially respond well to endocrine therapies, drug resistance often emerges and side effects can be challenging. To overcome drug resistance, the exploration for new drugs is a priority. Metal complexes have demonstrated significant antitumor activities, and platinum complexes are widely used in the clinic against various cancers, including breast cancer. In this Perspective, the first section describes the classification and mechanism of endocrine therapy drugs for ER+ breast cancer, and the second section summarizes research since 2000 into metal complexes with activity toward ER+ breast cancer. Finally, we discuss the opportunities, challenges, and future directions for metal complexes in the treatment of ER+ breast cancer.
Collapse
Affiliation(s)
- Zhenlin Liang
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China
| | - Lijuan Liu
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China
| | - Yanyu Zhou
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China
| | - Wukun Liu
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China.,State key Laboratory of Coordination Chemistry, Nanjing University, Nanjing, 210023, P. R. China
| | - Yunlong Lu
- Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China
| |
Collapse
|
2
|
Mal S, Jana M. Recent Advances on Synthesis of Fused Chromeno‐Quinoline Heterocycles under Transition Metal‐Free Condition. ChemistrySelect 2022. [DOI: 10.1002/slct.202103525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Sourav Mal
- Department of Chemistry University of Kalyani Kalyani 741235
| | - Manoranjan Jana
- Department of Chemistry University of Kalyani Kalyani 741235
| |
Collapse
|
3
|
Synthesis and biological evaluation of substituted amide derivatives of C4-ageratochromene dimer analog. Bioorg Med Chem Lett 2021; 50:128340. [PMID: 34469711 DOI: 10.1016/j.bmcl.2021.128340] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 08/19/2021] [Accepted: 08/21/2021] [Indexed: 12/22/2022]
Abstract
Substituted amide derivatives of C4-ageratochromene dimer analog (19) were synthesized through structural modification of precocene-I (4a), isolated from the essential oil of Ageratum conyzoides L. The target compounds (18-20, 23I-VI, 24I-VI, and 25I-VI) were evaluated for their bone-forming effect using osteoblast differentiation assay. Seven compounds (23I, 23II, 23IV, 23VI, 24III, 24VI, and 25VI) presented good activity within 1 pM-1 nM concentration. At 1 pM concentration, the most active compound i.e. 23II showed effective mineralization of osteoblast cells along with expression of osteogenic marker genes viz RUNX 2, BMP-2, and type 1 collagen (Type-1 col) without any toxicity towards osteoblast cells. Single crystal X-ray analysis of 18 and 20 revealed that the core nucleus of these molecules bear phenyl rings in a Trans-stilbenoid system and had a good structural correlation with 17β-estradiol (1) and diethylstilbestrol (DES, 3). In-silico study about 23II showed its structural complementarities with the LBD of estrogen receptor (ER) which indicated possible ER-mediated activity of compounds.
Collapse
|
4
|
Sharma R, Singh VJ, Chawla PA. Advancements in the Use of Platinum Complexes as Anticancer Agents. Anticancer Agents Med Chem 2021; 22:821-835. [PMID: 34353272 DOI: 10.2174/1871520621666210805150705] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 05/06/2021] [Accepted: 05/30/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND The platinum (II) complexes as anticancer agents have been well explored for the development of novel analogs. Yet, none of them achieved clinical importance in oncology. At present, anticancer compounds containing platinum (II) complexes have been employed in the treatment of colorectal, lung, and genitourinary tumors. Among the platinum-based anticancer drugs, Cisplatin (cis-diamine dichloroplatinum (II), cis-[Pt(NH3)2Cl2]) is one of the most potent components of cancer chemotherapy. The nephrotoxicity, neurotoxicity and ototoxicity, and platinum compounds associated resistant cancer are some major disadvantages. OBJECTIVE With the rapidly growing interest in platinum (II) complexes in tumor chemotherapy, researchers have synthesized many new platinum analogs as anticancer agents that show better cytotoxicity, and less off-target effects with less cellular resistance. This follows the introduction of oxaliplatin, water-soluble carboplatin, multinuclear platinum and newly synthesized complexes, etc. Method: This review emphasizes recent advancements in drug design and development, the mechanism of platinum (II) complexes, their stereochemistry, current updates, and biomedical applications of platinum-based anticancer agents. CONCLUSION In the last few decades, the popularity of platinum complexes as potent anti-cancer agents has risen as scientists have synthesized many new platinum complexes that exhibit better cytotoxicity coupled with less off-target effects.
Collapse
Affiliation(s)
- Rajiv Sharma
- Department of Pharmaceutical Chemistry School of Pharmaceutical Sciences, CT University, Ludhiana. India
| | - Vikram Jeet Singh
- Department of Pharmaceutical Chemistry, ISF College of Pharmacy, G.T. Road, Moga-142 001, Punjab. India
| | - Pooja A Chawla
- Department of Pharmaceutical Chemistry and Analysis, ISF College of Pharmacy, Moga-142001, Punjab. India
| |
Collapse
|
5
|
Mal S, Jana M. An unusual and facile N-hetero cyclisation of 2-amino-4-(2-oxo-2-arylethyl)-4H-chromene-3-carbonitrile derivatives using hypervalent iodine in alcohol under ambient condition. Tetrahedron Lett 2020. [DOI: 10.1016/j.tetlet.2020.152355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Chanphai P, Ouellette V, Mandal S, Mandal SK, Bérubé G, Tajmir-Riahi HA. Location of multiple binding sites for testo and testo-Pt(II) with tRNA. J Biomol Struct Dyn 2018; 37:4133-4139. [PMID: 30417741 DOI: 10.1080/07391102.2018.1541142] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We report the binding of testo and testo-Pt(II) complexes (testosterone derivatives) with tRNA in aqueous solution at physiological pH. Thermodynamic parameter ΔH0 -8 to -3 (kJ mol-1), ΔS0 35 to 18 (J mol-1K-1) and ΔG0 -14 to -13 (kJ mol-1) and other spectroscopic results showed drug-tRNA binding occurs via ionic contacts with testo-Pt(II) forming more stable tRNA complexes in comparison to testo: Ktesto-Pt(II)-tRNA= 3.2 (± 0.9) × 105 M-1 > Ktesto-tRNA= 2.1 (± 0.7) × 105 M-1. Molecular modeling showed multiple binding sites for testo and testo-Pt(II) on tRNA molecule. Some of the useful molecular descriptors are calculated. Major structural changes were observed for biopolymers upon drug complexation, while tRNA remains in the A-family structures.
Collapse
Affiliation(s)
- P Chanphai
- Department of Chemistry-Biochemistry and Physics, University of Québec at Trois-Rivières C. P. 500 , Trois-Rivières , QC , Canada
| | - V Ouellette
- Department of Chemistry-Biochemistry and Physics, University of Québec at Trois-Rivières C. P. 500 , Trois-Rivières , QC , Canada
| | - S Mandal
- Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Department of Physiology and Pathophysiology, College of Medicine, Rady Faculty of Health Sciences, University of Manitoba , Winnipeg , MB , Canada
| | - S K Mandal
- St. John's, Newfoundland, Canada and College of the North Atlantic, Faculty of Medicine, Memorial University of Newfoundland , Newfoundland , Canada
| | - G Bérubé
- Department of Chemistry-Biochemistry and Physics, University of Québec at Trois-Rivières C. P. 500 , Trois-Rivières , QC , Canada
| | - H A Tajmir-Riahi
- Department of Chemistry-Biochemistry and Physics, University of Québec at Trois-Rivières C. P. 500 , Trois-Rivières , QC , Canada
| |
Collapse
|
7
|
Ahmad MI, Dixit S, Konwar R, Vasdev PG, Yadav AK, Tripathi S, Gupta MM, Sharma A, Gupta A. Syntheses of conformationally restricted benzopyran based triarylethylenes as growth inhibitors of carcinoma cells. Bioorg Med Chem Lett 2017; 27:5040-5045. [DOI: 10.1016/j.bmcl.2017.09.060] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Revised: 09/02/2017] [Accepted: 09/29/2017] [Indexed: 01/13/2023]
|
8
|
Arodola OA, Soliman MES. Quantum mechanics implementation in drug-design workflows: does it really help? Drug Des Devel Ther 2017; 11:2551-2564. [PMID: 28919707 PMCID: PMC5587087 DOI: 10.2147/dddt.s126344] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
The pharmaceutical industry is progressively operating in an era where development costs are constantly under pressure, higher percentages of drugs are demanded, and the drug-discovery process is a trial-and-error run. The profit that flows in with the discovery of new drugs has always been the motivation for the industry to keep up the pace and keep abreast with the endless demand for medicines. The process of finding a molecule that binds to the target protein using in silico tools has made computational chemistry a valuable tool in drug discovery in both academic research and pharmaceutical industry. However, the complexity of many protein-ligand interactions challenges the accuracy and efficiency of the commonly used empirical methods. The usefulness of quantum mechanics (QM) in drug-protein interaction cannot be overemphasized; however, this approach has little significance in some empirical methods. In this review, we discuss recent developments in, and application of, QM to medically relevant biomolecules. We critically discuss the different types of QM-based methods and their proposed application to incorporating them into drug-design and -discovery workflows while trying to answer a critical question: are QM-based methods of real help in drug-design and -discovery research and industry?
Collapse
Affiliation(s)
- Olayide A Arodola
- Department of Pharmaceutical Chemistry, University of KwaZulu-Natal, Durban, South Africa
| | - Mahmoud ES Soliman
- Department of Pharmaceutical Chemistry, University of KwaZulu-Natal, Durban, South Africa
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Egypt
| |
Collapse
|
9
|
Zhang L, Yao YC, Gao MY, Rong RX, Wang KR, Li XL, Chen H. Anticancer activity and DNA binding property of the trimers of triphenylethylene–coumarin hybrids. CHINESE CHEM LETT 2016. [DOI: 10.1016/j.cclet.2016.05.027] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
10
|
Anticancer activity and DNA binding property of the dimers of triphenylethylene–coumarin hybrid with two amino side chains. Med Chem Res 2014. [DOI: 10.1007/s00044-014-1296-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
11
|
Wang L, Li WJ, Song YM. Antitumor activity and DNA binding studies on rare earth metal complexes with all-trans retinoic acid andl-glutamic acid. RSC Adv 2014. [DOI: 10.1039/c4ra07368a] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
12
|
Tan G, Yao Y, Gu Y, Li S, Lv M, Wang K, Chen H, Li X. Cytotoxicity and DNA binding property of the dimers of triphenylethylene–coumarin hybrid with one amino side chain. Bioorg Med Chem Lett 2014; 24:2825-30. [DOI: 10.1016/j.bmcl.2014.04.106] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Revised: 04/15/2014] [Accepted: 04/25/2014] [Indexed: 12/12/2022]
|
13
|
Zhao L, Yao Y, Li S, Lv M, Chen H, Li X. Cytotoxicity and DNA binding property of triphenylethylene–coumarin hybrids with two amino side chains. Bioorg Med Chem Lett 2014; 24:900-4. [DOI: 10.1016/j.bmcl.2013.12.084] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2013] [Revised: 12/18/2013] [Accepted: 12/19/2013] [Indexed: 12/30/2022]
|
14
|
Jacobs DL, Chan BC, O'Connor AR. N-[2-(Pyridin-2-yl)ethyl]-derivatives of methane-, benzene- and toluenesulfonamide: prospective ligands for metal coordination. Acta Crystallogr C 2013; 69:1397-401. [PMID: 24192196 DOI: 10.1107/s0108270113025341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Accepted: 09/12/2013] [Indexed: 11/10/2022] Open
Abstract
The molecular and supramolecular structures are reported of N-[2-(pyridin-2-yl)ethyl]methanesulfonamide, C8H12N2O2S, (I), N-[2-(pyridin-2-yl)ethyl]benzenesulfonamide, C13H14N2O2S, (II), and N-[2-(pyridin-2-yl)ethyl]toluenesulfonamide, C14H16N2O2S, (III). Although (II) and (III) are almost structurally identical, the N(amide)-C(ethyl)-C(ethyl)-C(pyridinyl) torsion angles for (I) and (II) are more closely comparable, with magnitudes of 175.37 (15)° for (I) and 169.04 (19)° for (II). This angle decreases dramatically with an additional methyl group in the para position of the sulfonamide substituent, resulting in a value of 62.9 (2)° for (III). In each of the three compounds there is an N-H...N hydrogen bond between the sulfonamide of one molecule and the pyridine N atom of a neighbor. Compound (I) forms hydrogen-bonded dimers, (II) uses its hydrogen bonding to connect supramolecular layers, and the hydrogen bonding of (III) connects linear chains to form layers. For arene-substituted (II) and (III), the different conformations afforded by the variable dihedral angles promote intermolecular π-π stacking in the benzene-substituted structure (II), but distorted intramolecular T-shaped π-stacking in the toluene-substituted structure (III), with a centroid-to-centroid distance of 4.9296 (10) Å.
Collapse
Affiliation(s)
- Danielle L Jacobs
- Department of Chemistry, Biochemistry and Physics, Rider University, 2083 Lawrenceville Road, Lawrenceville, NJ 08648, USA
| | | | | |
Collapse
|
15
|
Chen H, Li S, Yao Y, Zhou L, Zhao J, Gu Y, Wang K, Li X. Design, synthesis, and anti-tumor activities of novel triphenylethylene-coumarin hybrids, and their interactions with Ct-DNA. Bioorg Med Chem Lett 2013; 23:4785-9. [PMID: 23902804 DOI: 10.1016/j.bmcl.2013.07.009] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2013] [Revised: 06/28/2013] [Accepted: 07/02/2013] [Indexed: 10/26/2022]
Abstract
Novel triphenylethylene-coumarin hybrid derivatives containing different amounts of amino side chains were designed and synthesized in good yields under microwave radiation. The derivatives 5b-d which possessed two amino side chains (except morpholinyl) showed a broad-spectrum and good anti-proliferative activity against five tumor cells and low cytotoxicity in osteoblast. UV-vis, fluorescence, and circular dichroism (CD) spectroscopies and thermal denaturation exhibited that compounds 10 c, 5c, and 13c bearing amino side chain (except morpholinyl) on 4-phenyl had significant interactions with Ct-DNA by the intercalative mode of binding. Structure-activity relationships (SARs) analysis suggested that the amino alkyl chain would play an important role both in the compounds against tumor cells proliferation and their interactions with DNA.
Collapse
Affiliation(s)
- Hua Chen
- Key Laboratory of Chemical Biology of Hebei Province, College of Chemistry and Environmental Science, Hebei University, Baoding 071002, China
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. PLoS One 2013; 8:e66246. [PMID: 23840429 PMCID: PMC3686794 DOI: 10.1371/journal.pone.0066246] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2012] [Accepted: 05/07/2013] [Indexed: 11/19/2022] Open
Abstract
Inhibition of epidermal growth factor receptor (EGFR) signaling is considered to be a promising treatment strategy for estrogen receptor (ER)-negative breast tumors. We have investigated here the anti-breast cancer properties of a novel anti-proliferative benzopyran compound namely, 2-[piperidinoethoxyphenyl]-3-phenyl-2H-benzo(b)pyran (CDRI-85/287) in ER- negative and EGFR- overexpressing breast cancer cells. The benzopyran compound selectively inhibited the EGF-induced growth of MDA-MB 231 cells and ER-negative primary breast cancer cell culture. The compound significantly reduced tumor growth in xenograft of MDA-MB 231 cells in nude mice. The compound displayed better binding affinity for EGFR than inhibitor AG1478 as demonstrated by molecular docking studies. CDRI-85/287 significantly inhibited the activation of EGFR and downstream effectors MEK/Erk and PI-3-K/Akt. Subsequent inhibition of AP-1 promoter activity resulted in decreased transcription activation and expression of c-fos and c-jun. Dephosphorylation of downstream effectors FOXO-3a and NF-κB led to increased expression of p27 and decreased expression of cyclin D1 which was responsible for decreased phosphorylation of Rb and prevented the transcription of E2F- dependent genes involved in cell cycle progression from G1/S phase. The compound induced apoptosis via mitochondrial pathway and it also inhibited EGF-induced invasion of MDA-MB 231 cells as evidenced by decreased activity of MMP-9 and expression of CTGF. These results indicate that benzopyran compound CDRI-85/287 could constitute a powerful new chemotherapeutic agent against ER-negative and EGFR over-expressing breast tumors.
Collapse
|
17
|
|
18
|
Stokes S, Mustain R, Pickle L, Mead KT. Rhodium-catalyzed cyclopropanations of 2-aryl-2H-chromenes with dialkyl malonate esters. A comparison of α-diazo derivatives and phenyliodonium ylides. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.05.061] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Synthesis and cytotoxicity of cis-dichloroplatinum (II) complexes of (1S,3S)-1,2,3,4-tetrahydroisoquinolines. Eur J Med Chem 2011; 46:356-63. [DOI: 10.1016/j.ejmech.2010.11.025] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2010] [Revised: 11/09/2010] [Accepted: 11/15/2010] [Indexed: 11/17/2022]
|
20
|
Copper, gold and silver compounds as potential new anti-tumor metallodrugs. Future Med Chem 2010; 2:1591-608. [DOI: 10.4155/fmc.10.234] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Although platinum-based drugs such as cisplatin are powerful anticancer agents, they have undesirable side effects and are effective against only a few kinds of cancers. There is, therefore, a need for new drugs with an improved spectrum of efficacy and lower toxicity. Complexes of copper, gold and silver (coinage metals) are potential candidates to fullfill this need. The development of anticancer drugs based on these metals is currently a very active field. Considerable effort has also been put into elucidating the mechanisms of action of these complexes and optimizing their bioactivity through structural modification. In this review, we highlight recent developments in the design of coinage metal complexes with anti-tumor activity and discuss the emerging importance of quantitative structure–activity relationship methods in the study of anticancer metal complexes. Future work in this field, including likely coinage metal complexes that will attract attention, are proposed.
Collapse
|
21
|
Yaya AR, Touaibia M, Massarweh G, Rochon FD, Breau L. Synthesis of 17 alpha-substituted ethynylestradiols: potential ligands for drug vectors. Steroids 2010; 75:489-98. [PMID: 20302883 DOI: 10.1016/j.steroids.2010.03.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2010] [Revised: 03/08/2010] [Accepted: 03/09/2010] [Indexed: 01/23/2023]
Abstract
17alpha-substituted ethynylestradiols, derived from estrone, were converted to their corresponding 17 alpha-(bromo- or iodo-propargyl)estrone intermediates. Nucleophilic substitution onto these moieties with malonate diester followed by hydrolysis and complexation with cis-Pt(Me(2)en)I(2) (Me(2)en=N,N-dimethylethylenediamine) gave cis-Pt(Me(2)en)(2-(3-(17beta-estradiol-17 alpha-yl)-prop-2-ynyl)malonato) 7, thus demonstrating that these estrogen-derived compounds can be used to synthesize stable Pt(II) complexes. The 3-(17beta-estradiol-17 alpha-yl)-prop-2-ynyl-1-sulfanylethylthiol 23 was also prepared.
Collapse
Affiliation(s)
- Amadou R Yaya
- Département de Chimie, PharmaQAM, NanoQAM, Université du Québec à Montréal, Case Postale 8888, Succursale Centre-Ville, Montréal, Québec, Canada
| | | | | | | | | |
Collapse
|
22
|
Neves AP, da Silva GB, Vargas MD, Pinheiro CB, Visentin LDC, Filho JDBM, Araújo AJ, Costa-Lotufo LV, Pessoa C, de Moraes MO. Novel platinum(ii) complexes of 3-(aminomethyl)naphthoquinone Mannich bases: synthesis, crystal structure and cytotoxic activities. Dalton Trans 2010; 39:10203-16. [DOI: 10.1039/c0dt00572j] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
23
|
Gust R, Beck W, Jaouen G, Schönenberger H. Optimization of cisplatin for the treatment of hormone-dependent tumoral diseases. Coord Chem Rev 2009. [DOI: 10.1016/j.ccr.2009.02.029] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
24
|
Rational drug design. Eur J Pharmacol 2009; 625:90-100. [PMID: 19835861 DOI: 10.1016/j.ejphar.2009.06.065] [Citation(s) in RCA: 156] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Revised: 05/21/2009] [Accepted: 06/08/2009] [Indexed: 11/21/2022]
Abstract
In this article, current knowledge of drug design is reviewed and an approach of rational drug design is presented. The process of drug development is challenging, expensive, and time consuming, although this process has been accelerated due to the development of computational tools and methodologies. The current target based drug design approach is incomplete because most of the drugs developed by structure guided approaches have been shown to have serious toxic side effects. Otherwise these drugs would have been an ideal choice for the treatment of diseases. Hence, rational drug design would require a multidisciplinary approach. In this regard, incorporation of gene expression technology and bioinformatics tools would be indispensable in the structure based drug design. Global gene expression data and analysis of such data using bioinformatics tools will have numerous benefits such as efficiency, cost effectiveness, time saving, and will provide strategies for combination therapy in addition to overcoming toxic side effects. As a result of incorporation of gene expression data, partial benefit of the structure based drug design is slowly emerging and rapidly changing the approach of the drug development process. To achieve the full benefit of developing a successful drug, multidisciplinary approaches (approaches such as computational chemistry and gene expression analysis, as discussed in this article) would be necessary. In the future, there is adequate room for the development of more sophisticated methodologies.
Collapse
|
25
|
Zhou C, Gan L, Zhang Y, Zhang F, Wang G, Jin L, Geng R. Review on supermolecules as chemical drugs. SCIENCE IN CHINA. SERIES B, CHEMISTRY 2009; 52:415-458. [PMID: 38624300 PMCID: PMC7089408 DOI: 10.1007/s11426-009-0103-2] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/08/2008] [Accepted: 12/28/2008] [Indexed: 11/01/2022]
Abstract
Supramolecular medicinal chemistry field has been a quite rapidly developing, increasingly active and newly rising interdiscipline which is the new expansion of supramolecular chemistry in pharmaceutical sciences, and is gradually becoming a relatively independent scientific area. Supramolecular drugs could be defined as medicinal supermolecules formed by two or more molecules through non-covalent bonds. So far a lot of supermolecules as chemical drugs have been widely used in clinics. Supermolecules as chemical drugs, i.e. supramolecular chemical drugs or supramolecular drugs, which might have the excellences of lower cost, shorter period, higher potential as clinical drugs for their successful research and development, may possess higher bioavailability, better biocompatibility and drug-targeting, fewer multidrug-resistances, lower toxicity, less adverse effect, and better curative effects as well as safety, and therefore exhibit wide potential application. These overwhelming advantages have drawn enormous special attention. This paper gives the definition of supramolecular drugs, proposes the concept of supramolecular chemical drugs, and systematically reviews the recent advances in the research and development of supermolecules, including organic and inorganic complex ones as chemical drugs in the area of antitumor, anti-inflammatory, analgesic, antimalarial, antibacterial, antifungal, antivirus, anti-epileptic, cardiovascular agents and magnetic resonance imaging agents and so on. The perspectives of the foreseeable future and potential application of supramolecules as chemical drugs are also presented.
Collapse
Affiliation(s)
- ChengHe Zhou
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715 China
| | - LinLing Gan
- School of Pharmaceutical Sciences, Southwest University, Chongqing, 400715 China
| | - YiYi Zhang
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715 China
| | - FeiFei Zhang
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715 China
| | - GuangZhou Wang
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715 China
| | - Lei Jin
- School of Pharmaceutical Sciences, Southwest University, Chongqing, 400715 China
| | - RongXia Geng
- School of Chemistry and Chemical Engineering, Southwest University, Chongqing, 400715 China
| |
Collapse
|
26
|
Froehlich E, Gupta A, Provencher-Mandeville J, Asselin É, Bariyanga J, Bérubé G, Tajmir-Riahi HA. Study of DNA Interactions with Steroidal and Nonsteroidal Estrogen–Platinum (II)–Based Anticancer Drugs. DNA Cell Biol 2009; 28:31-9. [DOI: 10.1089/dna.2008.0804] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Emilie Froehlich
- Département de Chimie-Biologie, Groupe de Recherche en Biologie Végétale, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - Atul Gupta
- Département de Chimie-Biologie, Groupe de Recherche en Oncologie et en Endocrinologie Moléculaires, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - Josée Provencher-Mandeville
- Département de Chimie-Biologie, Groupe de Recherche en Oncologie et en Endocrinologie Moléculaires, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - éric Asselin
- Département de Chimie-Biologie, Groupe de Recherche en Oncologie et en Endocrinologie Moléculaires, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - Joseph Bariyanga
- Department of Chemistry, University of Hawaii-West O'ahu, Pearl City, Hawaii
| | - Gervais Bérubé
- Département de Chimie-Biologie, Groupe de Recherche en Oncologie et en Endocrinologie Moléculaires, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - Heidar-Ali Tajmir-Riahi
- Département de Chimie-Biologie, Groupe de Recherche en Biologie Végétale, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| |
Collapse
|